Study evaluated PECS Block with levobupivacaine and Dexmedetomidine for Pain Control After Mastectomy: Study

Breast surgery’s significant pain necessitates a substantial quantity of analgesics for postoperative pain relief. Recent study focused on postoperative pain management in female patients undergoing breast cancer surgery, particularly modified radical mastectomy (MRM). The researchers aimed to assess the effectiveness of the interfascial plane for the pectoral nerve (PECS) block, in combination with dexmedetomidine, in alleviating postoperative pain. The study involved 60 female patients who were randomized into two groups: one receiving 20 ml of 0.25% levobupivacaine (Group L) and the other receiving 20 ml of 0.25% levobupivacaine with 0.5 µg/kg of dexmedetomidine (Group DL). The primary outcome measured was the duration of analgesia.

Study Results

The results showed that the median time of the first analgesic requirement was 8 hours in Group L and 18 hours in Group DL, with a significant difference (P < 0.001). The mean total opioid consumption in the first 24 hours was 12.53 mg in Group L and 6.93 mg in Group DL. The study concluded that adding dexmedetomidine to levobupivacaine enhanced the duration of analgesia of direct PECS block in patients undergoing MRM, leading to extended postoperative analgesia and reduced opioid consumption.

Significance of PECS Block and Dexmedetomidine

The study highlighted the significance of PECS block in postoperative pain management for breast surgery, providing effective analgesia without significant side effects. It also pointed out the potential benefits of using dexmedetomidine as an adjuvant with levobupivacaine, including prolonged analgesia, reduced opioid consumption, and improved quality of postoperative analgesia. The findings suggested that dexmedetomidine enhances the effect of PECS block, and its addition can lead to more consistent and predictable analgesic outcomes.

Study Limitations and Recommendations

The study’s limitations included the absence of a passive control group and the use of the Numerical Rating Scale (NRS) score for pain assessment, which may be less accurate than the minimal clinically significant difference (MCID) in evaluating change in postoperative pain. The study recommended future clinical trials to evaluate the benefits and drawbacks of continuous, direct PECS block after placing an epidural catheter in the fascial plane and to assess the quality of recovery (QoR) score. The authors also suggested further research to determine whether a lesser volume can produce effective analgesia in direct PEC block and to explore the multifaceted benefits of direct PECS block.

Overall, the study provided valuable insights into postoperative pain management in female patients undergoing breast cancer surgery and emphasized the potential of using dexmedetomidine as an adjuvant with levobupivacaine for enhancing the efficacy of PECS block in alleviating postoperative pain.

Key Points –

– The study focused on postoperative pain management in female patients undergoing breast cancer surgery, specifically modified radical mastectomy (MRM). It aimed to assess the effectiveness of the interfascial plane for the pectoral nerve (PECS) block, combined with dexmedetomidine, in alleviating postoperative pain. The study involved 60 female patients randomized into two groups: one receiving 0.25% levobupivacaine and the other receiving the same with dexmedetomidine.

– Results showed that the median time of the first analgesic requirement was significantly longer in the Group receiving dexmedetomidine, with a mean total opioid consumption in the first 24 hours also being significantly lower in this group. The study concluded that adding dexmedetomidine to levobupivacaine enhanced the duration of analgesia of direct PECS block in patients undergoing MRM, leading to extended postoperative analgesia and reduced opioid consumption.

– The study highlighted the significance of PECS block in postoperative pain management for breast surgery, providing effective analgesia without significant side effects. It also pointed out the potential benefits of using dexmedetomidine as an adjuvant with levobupivacaine, including prolonged analgesia, reduced opioid consumption, and improved quality of postoperative analgesia. The findings suggested that dexmedetomidine enhances the effect of PECS block, and its addition can lead to more consistent and predictable analgesic outcomes. The study recommended future clinical trials to evaluate the benefits and drawbacks of continuous, direct PECS block after placing an epidural catheter in the fascial plane and to assess the quality of recovery (QoR) score.

Reference –

Arun N, Avinash R, Choudhary A. Intraoperative thoracic interfascial plane block with levobupivacaine versus levobupivacaine with dexmedetomidine for postoperative

analgesia after modified radical mastectomy: A randomised controlled double‑blinded trial. Indian J Anaesth 2024;68:686‑92

Powered by WPeMatico

UP DGME Releases Round 1 NEET MDS Counselling 2024 Schedule, details

Uttar Pradesh- Uttar Pradesh Director General, Medical Education (UPDGME) has released the schedule for the 1st round of online counselling for admission to state quota seats of the Master of Dental Surgery (MDS) course in Government/Private Dental Colleges/Universities of Uttar Pradesh.

As per the schedule, the registration for online counselling for UP NEET MDS 2024 will begin on July 10, 2024, at 5:00 PM and will continue till July 15, 2024, at 11:00 AM.

Below is the detailed schedule-

S.NO

DESCRIPTION

DATES

TOTAL DAYS

1

Date of online registration.

10’h July 2024 (From 5:00 PM) To 15th July 2024 (Till 11:00 AM).

05 days.

2

Date of depositing registration fee and security Fee.

10th July 2024 (From 5:00 PM) To 15th

July 2024 (Till 5:00 PM).

05 days.

3

Date of declaration of merit list.

15″ July 2024.

01 days.

4

Date of online choice filling.

16″ July 2024 (From 11:00 AM) to 18th July 2024 (Till 5:00 PM)

19 July 2024.

03 days.

5

Date of declaration of result of seat allotment.

19th July 2024.

01 days.

6

Date for downloading allotment letters and admission process.

20th July 2024 to 25″ July 2024.

06 days.

Below is the MCC NEET MDS detailed schedule-

S.NO

SCHEDULE FOR ADMISSION

ALL INDIA QUOTA/DEEMED & CENTRAL UNIVERSITIES

SHARING OF JOINED CANDIDATE’S DATA BY MCC

STATE COUNSELLING

SHARING OF JOINED CANDIDATE’S DATA BY STATES

1

Ist Round of Counselling.

1st July, 2024 to 10th July, 2024.

19th July, 2024.

10th July to 20th July, 2024.

26th July to 27th July, 2024.

2

Last date of Joining.

The last date of Joining is 17th July 2024.

25th July, 2024.

3

2nd round of Counselling.

7 th Aug, 2024

12th Aug, 2024.

4

Round-3.

12th Aug to 21st Aug, 2024.

29th Aug., 2024.

21st Aug 2024 to 26th Aug, 2024.

31st Aug.,2024.

5

Last date of joining.

28th Aug., 2024.

30th Aug., 2024.

6

Stray Vacancy.

2nd Sept., 2024 to 7th Sept., 2024.

5th Sept., 2024 to 10th Sept., 2024.

7

Last date of joining.

14th Sept., 2024.

14th Sept., 2024.

The UP DGME also known as Uttar Pradesh Directorate General of Medical Education, is the Department of Medical Education plays a pivotal role in developing medical and para-medical personnel to cater to the state’s health needs.

To view the schedule, click the link below

Powered by WPeMatico

Oxytocin possible treatment for obesity and postnatal depression, points Genetic study

Scientists have identified a gene which, when missing or impaired, can cause obesity, behavioural problems and, in mothers, postnatal depression. The discovery, reported today in Cell, may have wider implications for the treatment of postnatal depression, with a study in mice suggesting that oxytocin may alleviate symptoms.

Obesity and postnatal depression are significant global health problems. Postnatal depression affects more than one in 10 women within a year of giving birth and is linked to an increased risk of suicide, which accounts for as many as one in five maternal deaths in high income countries. Meanwhile, obesity has more than doubled in adults since 1990 and quadrupled in adolescents, according to the World Health Organization.

While investigating two boys from different families with severe obesity, anxiety, autism, and behavioural problems triggered by sounds or smells, a team led by scientists at the University of Cambridge, UK, and Baylor College of Medicine, Houston, USA, discovered that the boys were missing a single gene, known as TRPC5, which sits on the X chromosome.

Further investigation revealed that both boys inherited the gene deletion from their mothers, who were missing the gene on one of their X chromosomes. The mothers also had obesity, but in addition had experienced postnatal depression.

To test if it was the TRPC5 gene that was causing the problems in the boys and their mothers, the researchers turned to animal models, genetically-engineering mice with a defective version of the gene (Trpc5 in mice).

Male mice with this defective gene displayed the same problems as the boys, including weight gain, anxiety, a dislike of social interactions, and aggressive behaviour. Female mice displayed the same behaviours, but when they became mothers, they also displayed depressive behaviour and impaired maternal care. Interestingly, male mice and female mice who were not mothers but carried the mutation did not show depression-like behaviour.

Dr Yong Xu, Associate Director for Basic Sciences at the USDA/ARS Children’s Nutrition Research Center at Baylor College of Medicine, said: “What we saw in those mice was quite remarkable. They displayed very similar behaviours to those seen in people missing the TRPC5 gene, which in mothers included signs of depression and a difficulty caring for their babies. This shows us that this gene is causing these behaviours.”

TRPC5 is one of a family of genes that are involved in detecting sensory signals, such as heat, taste and touch. This particular gene acts on a pathway in the hypothalamus region of the brain, where it is known to control appetite.

When the researchers looked in more detail at this brain region, they discovered that TRPC5 acts on oxytocin neurons – nerve cells that produce the hormone oxytocin, often nicknamed the ‘love hormone’ because of its release in response to displays of affection, emotion and bonding.

Deleting the gene from these oxytocin neurons led to otherwise healthy mice showing similar signs of anxiety, overeating and impaired sociability, and, in the case of mothers, postnatal depression. Restoring the gene in these neurons reduced body weight and symptoms of anxiety and postnatal depression.

In addition to acting on oxytocin neurons, the team showed that TRPC5 also acts on so-called POMC neurons, which have been known for some time to play an important role in regulating weight. Children in whom the POMC gene is not working properly often have an insatiable appetite and gain weight from an early age.

Professor Sadaf Farooqi from the Institute of Metabolic Science at the University of Cambridge said: “There’s a reason why people lacking TRPC5 develop all of these conditions. We’ve known for a long time that the hypothalamus plays a key role in regulating ‘instinctive behaviours’ – which enable humans and animals to survive – such as looking for food, social interaction, the flight or fight response, and caring for their infants. Our work shows that TRPC5 acts on oxytocin neurons in the hypothalamus to play a critical role in regulating our instincts.”

While deletions of the TRPC5 gene are rare, an analysis of DNA samples from around 500,000 individuals in UK Biobank revealed 369 people – around three-quarters of whom were women – that carried variants of the gene and had a higher-than-average body mass index.

The researchers say their findings suggests that restoring oxytocin could help treat people with missing or defective TRPC5 genes, and potentially mothers experiencing postnatal depression.

Professor Farooqi said: “While some genetic conditions such as TRPC5 deficiency are very rare, they teach us important lessons about how the body works. In this instance, we have made a breakthrough in understanding postnatal depression, a serious health problem about which very little is known despite many decades of research. And importantly, it may point to oxytocin as a possible treatment for some mothers with this condition.”

There is already evidence in animals that the oxytocin system is involved in both depression and in maternal care and there have been small trials into the use of oxytocin as a treatment. The team say their work provides direct proof of oxytocin’s role, which will be crucial in supporting bigger, multi-centre trials.

Professor Farooqi added: “This research reminds us that many behaviours which we assume are entirely under our control have a strong basis in biology, whether that’s our eating behaviour, anxiety or postnatal depression. We need to be more understanding and sympathetic towards people who suffer with these conditions.”

This work was supported by Wellcome, the National Institute for Health and Care Research (NIHR), NIHR Cambridge Biomedical Research Centre, Botnar Fondation and Bernard Wolfe Health Neuroscience Endowment.

Reference: Li, Y, Cacciottolo, TM & Yin, N. Loss of Transient Receptor Potential Channel 5 Causes Obesity and Postpartum Depression. Cell; 2 July 2024; DOI: 10.1016/j.cell.2024.06.001

Powered by WPeMatico

Zydus Lifscience Gets CDSCO Panel Nod to Manufacture, Market Nivolumab for Metastatic Non-small Cell Lung Cancer

New Delhi: In a significant development, the drug major Zydus Life Sciences has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market Nivolumab 10mg/mL liquid solution for intravenous infusion for the indication locally advanced or metastatic non-small cell lung cancer (NSCLC).

In addition to the above, the expert panel approved the applied additional indications that are already approved for innovator products in India, subject to the condition that the firm shall conduct a Phase IV study in the country for all approved indications, including locally advanced or metastatic non-small cell lung cancer (NSCLC).

This came after Zydus Life Sciences presented their proposal for a grant of permission to manufacture and market Nivolumab 10 mg/mL liquid solution for intravenous infusion based on the results of a comparative Phase III clinical trial conducted in India to establish the efficacy, safety, pharmacokinetics, and immunogenicity of the drug product in locally advanced or metastatic non-small cell lung cancer (NSCLC).

In continuation with the above, Zydus Life Sciences also presented the proposal for approval of additional indications by way of extrapolation in line with indications approved for innovator products based on prescribing information.

Nivolumab is a PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.

The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells and and restoring a patient’s tumor-specific T-cell response.

Nivolumab is used alone or with other drugs to treat certain types of classic Hodgkin lymphoma, colorectal cancer, esophageal cancer, gastroesophageal junction cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma (a type of liver cancer), malignant pleural mesothelioma, melanoma, and non-small cell lung cancer.

At the recent SEC meeting for oncology held on June 18, 2024, the expert panel reviewed the proposal presented by Zydus Lifesciences for the grant of permission to manufacture and market Nivolumab 10 mg/mL liquid solution for intravenous infusion.

After detailed deliberation, the committee recommended the grant of permission to manufacture and market Nivolumab 10 mg/mL liquid solution for intravenous infusion for the indication of locally advanced or metastatic non-small cell lung cancer (NSCLC).

Furthermore, the committee recommended approval of the applied additional indications that are already approved for innovator products in India subject to the condition that the firm shall conduct a Phase IV study in the country for all approved indications including locally advanced or metastatic non-small cell lung cancer (NSCLC).

In accordance with the above, the expert panel suggested that the protocol to conduct the Phase IV study should be submitted within three months of grant of marketing authorization permission to manufacture and market the product.

Also Read: CDSCO Panel Approves AstraZeneca pharma’s Protocol Amendment proposal to study Anifrolumab

Powered by WPeMatico

Negligence Leading To Patient’s Vegetative State: Private Medical College Slapped Rs 51 Lakh Compensation, Rs 75,000 Monthly pay to kin

Chennai: The District Consumer Disputes Redressal Commission, Kancheepuram recently directed the Tagore Medical College and Hospital to pay Rs 51,14,431 as compensation to a man whose mother went into a vegetative state after suffering anaphylaxis shock due to the administration of Injection Ceftriaxone.
While considering the complaint, the Commission observed that to treat the patient’s Urinary Tract Infection, the hospital administered Xone without any test-dose and without administering other medicines first.
Apart from the lumpsum compensation, the hospital has also been directed to pay Rs 75,000 per month from 01.05.2024 to the patient’s lifetime, towards her recurring medical and maintenance charges.
The history of the case goes back to 2021 when the complainant took his mother to the treating hospital for a Urinary infection. It was the allegation of the complainant that despite informing the treating hospital about the allergies, the patient was administered with Injection Ceftriaxone, after which she suffered anaphylaxis shock.
It was contended by the complainant’s counsel that E-Coli is considered the most predominant cause of UTIs and according to the accepted medical practice, antibiotics such as co-trimoxazole (trimethoprim/sulfamethoxazole), nitrofurantoin, ciprofloxacin and ampicillin are prescribed for the treatment of UTIs.
However, the doctors in the hospital administered Ceftriaxone, a steroidal antibiotic that can be prescribed only after ensuring that other antibiotics do not subsidize the infection, without administering any test dose.
While the treating hospital argued that the E-Coli was sensitive and drug-resistant, the complainant’s counsel contended that they concluded without any medical/clinical/blood/urine report, test report and without trying any empirical treatment. He argued that without administering any drugs to heal the infection, the treating doctors cannot conclude that the E. coli that infected the patient was drug resistant.
Further, the complainant submitted that the hospital had withheld the complete medical records and bills breakup details despite several followups. At the time of discharge, the hospital has a one-page bill summary with a lot of discrepancies. However, the hospital had not shared the complete medical reports and detailed breakup of the bills despite several follow-ups until the direction of the Tamil Nadu Medical Council.
On the other hand, the counsel for the hospital submitted that a test dose of Inj.Ceftriaxone was administered to the complainant’s mother, to ascertain whether she was allergic to the said drug or not. As per the accepted medical practice, the patient was observed for allergic symptoms for the above medicine for more than 15 minutes.
However, since the patient did not show any allergic symptoms for the said drug, the complainant’s mother was again reviewed. Since the patient did not show any allergic symptoms for the above-mentioned drug, at 5.45 PM, the complainant’s mother was again reviewed. After checking her vitals and the vitals of the patient was stable, she was administered the remaining quantity of the above said drug, Ceftriaxone. It was also recorded in the Doctor’s orders and subsequently, the patient became semi-conscious and disoriented.
It was argued that there were no lapses in completing the billing process or there was no need for refusal to give the report of the complainant’s mother to get a second opinion. In fact the complainant was provided with all the papers pertaining to the treatment of the complainant’s mother at the time of discharge.
While considering the matter, the consumer court referred to the Supreme Court orders in the cases of Dr Laxman Balkrishna Joshi v Dr Trimbak Bapu Godbole, Jacob Mathew v State of Punjab, Martin F D’Souza v Mohd. Ishfaq etc and noted, “In the practice of medicine, there could be varying approaches to treatment. There can be a genuine difference of opinion. However, while adopting a course of treatment, the medical professional must ensure that it is not unreasonable. The threshold to prove unreasonableness is set with due regard to the risks associated with medical treatment and the conditions under which medical professionals function. This is to avoid a situation where doctors resort to ‘defensive medicine’ to avoid claims of negligence, often to the detriment of the patient. Hence, in a specific case where unreasonableness in professional conduct has been proven with regard to the circumstances of that case, a professional cannot escape liability for medical evidence merely by relying on a body of professional opinion.”
Concerning the case, the consumer court considered the allegation that the hospital did not provide the medical records to the complainant. After considering the single sheet discharge summary provided at the time of discharge and the document provided after the directions from the Tamil Nadu Medical Council, the consumer court noted that both the documents were written in different manners and the contents were also different.
“Hence, it is proved that the Medical records were made/rewritten for the purpose of the case,” observed the Commission.
“The opposite party failed to file the Initial assessment –Nursing pertaining to the present case, for the reasons best known to them. Thus, there is merit in the contention of the complainant’s counsel that the medical/clinical records were not furnished to the complainant at the time of discharge. The Opposite parties also failed to file any documents to prove that the clinical/medical records were furnished to the complainant at the time of discharge, or when the same was demanded by the complainant for obtaining second opinion,” it further noted.
“A perusal of discharge summary in Ex-B2 would reveal that the Opposite party hospital was in the practice issuing computerised discharge summary. In the present case, the Opposite party issued manual discharge summary for the reasons best known to the opposite party. Ex-A2 is the discharge summary issued on 3.7.2021. Ex-A29 is the discharge summary which contains the copy of the discharge summary furnished on 8.12.2021 by the Opposite party in response to the direction of Medical Council as well as the copy of the discharge summary issued to complainant on 3.7.2021. It is visible that both are different,” observed the District Consumer Court.
While considering the other allegations, the Commission took note of the hospital’s claim that the patient’s blood sample was taken on 27.06.2021. Allegedly, the urine samples were also taken on the same day and the urine culture report revealed that the Urinary infection was due to E-Coli (bacteria) and also the fact that the case was sensitive and drug-resistant.
The consumer court recorded that it could not read both the blood sugar and urine culture report but the relevant data was orally submitted by the counsel for the hospital. The commission took note of the report of the alleged sample taken on 30.06.2021 and the report of the alleged sample taken on 27.06.2021 and also noted that the patient did not attend the hospital on 27.06.2021.
“If the patient had reported the hospital on 30.06.2021 and if the blood sample was taken again on 30.06.2021 as alleged in para 4 of response to complainant averments, it is the opposite party who should prove on whose prescription, the blood sample (ex.B6) was taken on 30.06.2021 at about 11.46 A.M,” noted the Commission.
“According to the complainant, blood and urine samples were taken on 26.06.2021. The opposite party also admitted the same in the response field to complaint averments in para 4. A perusal of Ex.B6 would prove that the sample was taken on 27.6.2021. Ex.B8 would reveal that sample was collected on 30.6.2021. Therefore, it is proved that both Ex-B6 and B8 were fabricated for the purpose of this complaint. Therefore there is merit in the contention of the complainant’s counsel that manipulation of medical record amount to unfair trade practice,” it further observed.
After perusing the medical records, the consumer court noted that till 5.20 PM on 30.06.2021, no medicine was administered to the patient. Allegedly, the test dose of Xone was given at about 5.20 PM and the injection Xone was administered at about 5.45 PM. Thereafter, at around 5.55 PM, the patient was semi-unconscious, disoriented, and not responding with frothy discharge from mouth to nose and she was handed over to the Emergency intensive care unit.
However, the drug chart proved the contrary, noted the Commission. The drug chart had two entries, the first one was recorded at 5.50 PM on 30.06.2021 and the second one was recorded at 5.20 PM on 30.06.2021.
Taking note of this, the Consumer Court observed,

“If the test dose was given to the patient at 5.20PM of 30.6.2021, it should have been entered as 1st entry. Therefore it is proved that between 2.00PM and 5.50PM no drug except Inj-PAN was administered to the patient Sivagami till 5.50 and the said fact was entered in Drug Chart Ex-B7. The Inj.Xone was also administered without test dose and to cover up the said negligence Ex-B7 was manipulated and 2nd entry was made to show that test dose of Xone was administered at 5.20 PM on 30.6.2021.”

“Further as we have already discussed above, Ex-B7 is a drug chart which should contain the entries of medicines administered to the patient Sivagami from the time of admission on 30.6.2021 to till the discharge on 3.7.2021. In the present case, ExB7 alleged drug does not bear the details of drugs administered to the patient between 30.06.2021 to 03.07.2021 except the above two entries. Thus it is also proved that Ex-B7 was also created/fabricated for the purpose of this case,” it further noted.

“What was the purpose of admitting the patient as if there was an imminent danger to her life, when the hospital has not given any medicine between 2.00 PM and 5.50 PM,” said the Consumer Court.
Apart from this, the consumer court also observed that the hospital did not obtain informed consent, but obtained consent by coercion. It also questioned why huge volumes of vecuronium bromide were prescribed and why the same was not administered.
The Commission held that it was proved that Xone was administered without a test dose. Holding the hospital guilty of medical negligence, the Commission noted,

“By such act of administering Xone, an antibiotic which should have been administered as a final choice to treat UTI caused by E.coli especially when the patient is with comorbidities, it is proved that the conduct of the doctors and the hospital staff of opposite party fell below the standards of a reasonably competent practitioner in his field. As a result the patient had Anaphylaxis shock . Such act of the Opposite parties constitute medical negligence and deficiency in service as defined in section2(11) of Consumer Protection Act, 2019. Till date the patient had not recovered from her unconsciousness.”

“It is also proved that the Opposite party hospital has indulged in manipulating medical records to cover up the negligent acts of the doctors employed by it. The Opposite parties miserably failed to explain why 25 vials were prescribed and to whom 5 vials were administered. Such act of the opposite party amounts to unfair trade practice as defined in section2(47) of Consumer Protection Act, 2019,” it further noted.

The consumer court observed that because of the hospital’s negligence, the complainant’s mother had become a vegetable and his family was contained to manage their mother with 24×7 nursing assistant with requisite equipment. The Commission noted that such recurring expenses may continue up to the patient’s life-time assessed such expenses as Rs 75,000 per month, in addition to the expenses paid by the complainant’s family towards recurring treatment charges paid to the treating hospital and SRM SIMS Chennai. It also considered the fact that the complainant’s father lost his companion and also held that the complainant was entitled to compensation for mental agony, deficiency in service, and unfair trade practice.
Considering all these factors, the consumer court directed the hospital to pay Rs 89,431, the amount paid by the complainant as medical bill, Rs 50 lakh as damages towards monetary loss and mental agony suffered by the complainant, and Rs 25,000 towards cost of proceedings to the complainants.
Apart from this, the Commission also directed the hospital to pay the complainant a sum of Rs 75,000 per month from 01.05.2024 to the patient’s life-time towards her recurring medical and maintenance charges.
To read the order, click on the link below:

Powered by WPeMatico

Assistant Professor Post At Kerala Public Service Commission, Apply Now

Kerala: The Kerala Public Service Commission (KPSC) has released Vacancies for Assistant Professor posts on Direct Recruitment Basis in Medical Education Department. The selection will be done based on the written exam and interview.

KPSC is a body created by the Constitution of India. The Commission advise the Government on all matters relating to civil services referred to it under Article 320 (3) of the Constitution and publish notifications inviting applications for selection to various posts as per the requisitions of the appointing authorities, conduct written test and/or practical tests, physical efficiency test and interview, prepare ranked list based on the performance of the candidates and advise candidates for appointment strictly based on their merit and observing the rules of reservation as and when vacancies are reported. The Head Office of the Kerala Public Service Commission is situated at Pattom, Thiruvananthapuram, the State Capital.

KPSC Vacancy Details:

Total no of vacancies: Anticipated

The Vacancies are in the Department of Ophthalmology.

Last Date of Application: 17th July 2024 up to 12.00 Midnight.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=KPSC&location=&job_sector=all

Method of Submitting Applications:-

a) Candidates must register as per ‘ONE TIME REGISTRATION’ with the Official Website of Kerala Public Service Commission www.keralapsc.gov.in before applying for the post. Candidates who have registered can apply by logging on to their profile using their User-ID and password. Candidates must click on the ‘Apply Now’ button of the respective posts in the Notification to apply for the post.

The photograph uploaded should be one taken after 31.12.2014. Candidates who have created new Profile from 01.01.2024 should upload their Photograph taken within a period of 6 months. Name of the candidate and the date of photograph taken should be printed legibly at the bottom portion. The photograph once uploaded meeting all requirements shall be valid for 10 years from the date of uploading.

There is no change in other instructions regarding the uploading of photographs. No application fee is required. Candidates are responsible for the correctness of the personal information and secrecy of password. Before the final submission of the application on the profile candidates must ensure correctness of the information in their profile. They must quote the User-ID for further communication with the Commission. Application submitted is provisional and cannot be deleted or altered after submission. Candidates are advised to keep a printout or soft copy of the online application for future reference. Candidates can take the print out of the application by clicking on the link `My applications’ in their profile. All correspondence with the Commission, regarding the application should be accompanied with the print out of the application.

The application will be summarily rejected if non-compliance with the notification is found in due course of processing. Original Documents to prove qualification, experience, age, Community etc. have to be produced as and when called for. The profile correction made by the candidates themselves or through the office of the KPSC on request after the last date fixed for the receipt of applications will not be reflected in the application. Such corrections will come into effect only on the date on which corrections have been made.

b) If written/OMR/Online Test is conducted as part of this selection, candidates shall submit a confirmation for writing the examination through their One Time Registration Profile. Such candidates alone can generate and download the Admission Tickets in the last 15 days till the date of Test. The applications of candidates who do not submit confirmation within the stipulated period, will be rejected absolutely. The periods regarding the submission of confirmation and the availability of Admission Tickets will be published in the Examination Calender itself. Information in this regard will be given to the candidates in their respective profiles and in the Mobile Phone Number registered in it.

c) “Candidates who have AADHAAR Card should add AADHAAR as ID Proof in their profile.”

Powered by WPeMatico

JnJ gets USFDA, European Commission nod for Sirturo

Beerse: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has issued traditional approval for SIRTURO (bedaquiline) as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid. With the FDA’s approval, label restrictions that were included when the medicine was granted accelerated approval in the U.S. in December 2012 are removed.

The European Commission (EC) has also granted full approval of SIRTURO, converting its Conditional Marketing Authorisation to a Standard Marketing Authorisation, following a positive opinion in April 2024 from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

The approvals were supported by results from the Phase 3 STREAM Stage 2 study (NCT02409290), the first large-scale, randomized, multi-country open-label clinical study to evaluate the efficacy and safety of an all-oral bedaquiline-containing regimen for treatment of MDR-TB. Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens. Findings from the study were published in The Lancet in November 2022.

Read also: JnJ Orthopaedics Company DePuy Synthes gets 510(k) FDA clearance of VELYS Robotic-Assisted Solution for use in Unicompartmental Knee Arthroplasty Procedures

SIRTURO was granted accelerated approval by the FDA in December 2012 and conditional approval by the EMA in March 2014 following positive Phase 2 study data. A supplemental New Drug Application was submitted to the FDA in August 2023 to support the transition to full approval in the U.S. in addition to a Type II variation filed with the European Medicines Agency (EMA) in November 2023 to support the transition to Standard Marketing Authorisation.

Read also: JnJ submits application to USFDA for Subcutaneous amivantamab for patients with EGFR-mutated non-small cell lung cancer

Powered by WPeMatico

DCI gives deadline to dental Colleges to Upload MDS students’ details

New Delhi- A letter has been issued by the Deputy Secretary, Dental Council of India (DCI), to the principals of all dental colleges in India regarding uploading the details of students admitted to MDS/PG Diploma courses in dental colleges for the academic session 2024-25 on the official website of DCI.

Through the letter, Mr Kumar has stated that as per the Counseling Schedule issued by the Medical Counselling Committee (MCC) for Online Counseling (Allotment Process) for National Eligibility- Entrance Test (NEET) 50% AIQ and 100% Deemed / Central Universities & State Quota seats for MDS Courses for the academic year 2024, the MCC declared that the last date for joining is 14th September 2024 and the commencement of academic session for PG Courses is 1st August, 2024 for the academic year 2024-25.

On this, the college authorities of all dental colleges are hereby directed to upload the details of students, admitted to MDS / PG Diploma Course(s) at their dental institution for the academic session 2024-25, on DCI Website, using their already allotted login credentials for admissions on or before the last date of joining i.e. 14th September 2024 (12:00 midnight), positively.

It is also informed, that only uploaded details of students on the DCI Website will be considered and any detail of students received in any other format viz. e-mail or hard copy will not be considered at all, therefore, the college authorities are requested not to send the subject details through e-mail or post or any other mode. It is also stated that no request for an extension of time to upload the above details of students or any other excuse or reason of technical fault, etc. will be considered, therefore, the college authorities are again requested to ensure and make available all arrangements at your end to complete the above task, in time, to avoid any litigation and to enable this Council to take necessary action in a time bound manner.

IMPORTANT POINTS

1 To ensure the smooth uploading of the details of students and to avoid unnecessary delay, undue pressure and technical faults on the network, in uploading the details of the students at the last moment of the cut-off date, each and every dental institution shall make its efforts to upload the details of students gradually, immediately after the date of joining of student of each round of counselling, but not later than 12.00 Midnight of 14th September 2024 in any circumstance. In other words, the college shall not wait to upload the details of its students for the last moment of the cut-off date and the details would be uploaded by the college after each round of counselling.

2 Moreover, it has come to notice that some dental colleges upload the details of students who are not admitted to their college, because of which the college where the student has actually taken admission is unable to upload the details. Colleges are hereby strictly warned to upload the details of only the genuine and bonafide admissions of their college. The onus of furnishing true, correct and authentic information is upon the college concerned and in case of furnishing any wrong/incorrect information, it shall be open to DCI to initiate action against / penalize the college.

3 Only the uploaded details of students on the DCI portal shall be forwarded to the State Dental Councils / Tribunals for addition of MDS / PG Diploma Qualification.

Furthermore, in case of any difficulty, the college authorities may contact DCI for technical support. All the concerned competent authorities are requested to kindly ensure that the college authorities comply with the above stipulations in totality. This issues with the approval of the competent authority.

To view the letter, click the link below

Powered by WPeMatico

HC seeks status report on availability of doctors, PET scan machines in J&K hospitals

Jammu: The High Court of Jammu & Kashmir and Ladakh has asked the government to provide a status report on
the appointment of doctors and the installation of PET scan machines across the state.

The court’s directive
came while hearing a Public Interest Litigation (PIL) that seeks judicial
intervention to improve basic healthcare services for cancer treatment in Jammu
and Kashmir, reports Greater Kashmir. The division bench, comprising Chief Justice N. Kotiswar Singh and
Justice Moksha Khajuria Kazmi, requested Advocate General D. C. Raina to assist
in the proceedings. The case has been scheduled for further hearing on July 16.

“Keeping in view the
importance of the issue, we request the learned Advocate General to assist the
Court in the matter and file a brief status report with regard to appointment
of doctors and installation of PET Scan machines,” said the Court. 

The petition, filed in
2017, calls for the government to ensure the availability of sufficient
oncologists, onco-surgeons, and PET scan machines necessary for the treatment
of various cancers. The court’s decision to seek a detailed report highlights
the pressing need for enhanced cancer care infrastructure and professional
medical support in the region.

Medical Dialogues team had earlier reported that in a significant move to enhance the quality of medical education and streamline the faculty structure, the Administrative Council of Jammu and Kashmir, chaired by Lieutenant Governor Manoj Sinha, approved the implementation of a 3-Tier Faculty Structure in Government Medical Colleges and Super Specialty Hospitals in both Jammu and Srinagar. This decision aligns with the National Medical Commission’s (NMC) guidelines and mirrors the system in the new Government Medical Colleges in J&K.

The approved reform involves the upgrading of 287 Lecturer positions to Assistant Professors, ensuring adherence to the minimum teacher eligibility qualifications in medical institutes mandated by the NMC. 

Powered by WPeMatico

Amrita Hospital Doctors perform first Robot-Assisted Surgery for rare colon tumour in 67-year-old Uzbekistan man

Faridabad: In a groundbreaking surgical feat, a 67-year-old man from Uzbekistan was treated for his rare colonic tumour at Amrita Hospital, Faridabad marking the world’s first robot-assisted surgery for the condition. 

The patient, from Uzbekistan, had a special condition where his liver and colon were positioned differently (situs inversus partial) and he had a malignant tumour in this mispositioned colon.

The tumour was found to be a rare variant of colonic malignancy. The urgency of the surgery for the patient was high due to the tumor causing an obstruction in his large intestine, preventing him from eating solid foods, and posing a risk of spread and complications.

The surgery, which lasted about six hours, was performed by the Department of Gastrointestinal Surgery at Amrita Hospital, Faridabad. The surgery was led by Abhishek Agrawal and his team included Prof. Puneet Dhar, and Dr. Saleem Naik.

Also Read:Amrita Hospital Faridabad conducts first-ever Valve Replacement using Harmony Transcatheter Pulmonary Valve in patients heart

Dr Abhishek Agrawal, Robotic GI Oncosurgery Consultant, Department of Gastrointestinal Surgery, Amrita Hospital, Faridabad said, “Robot-assisted surgery significantly enhances precision and accuracy during procedures through its advanced features. The operation was conducted using a console that provides a magnified, high-resolution 3D view of the surgical site, offering superior depth perception and detailed anatomical visuals.

The robotic instruments used can bend and rotate with far greater dexterity than the human hand, enabling complex and precise movements. Additionally, these systems include tremor filtration technology, which eliminated the natural hand tremors of the surgeon, resulting in steadier and more controlled actions. These capabilities collectively contribute to more accurate targeting and removal of tumors, preservation of healthy tissues, and overall improved surgical outcomes.”

Situs inversus partial is quite rare, with overall incidence (including both totalis and partial) being approximately 1 in 10,000 people. However, partial forms are less frequently reported, and precise incidence rates for partial situs inversus specifically are not well-documented due to its rarity and variability. Situs inversus partial, where some internal organs are mirrored, is often genetic and may involve mutations or autosomal recessive traits.

Untreated, it can lead to misdiagnosis and delayed treatment of acute conditions like appendicitis, potentially life-threatening if not promptly addressed. Associated congenital anomalies can cause functional issues, and gastrointestinal problems, such as increased risk of bowel obstruction or volvulus, may arise, particularly with organs like a right-sided sigmoid colon.

Dr Puneet Dhar, HoD, Gastrointestinal Surgery, Amrita Hospital, Faridabad said, “The surgery was particularly challenging due to the anatomical variation in the patient, necessitating modifications in both patient positioning and the positioning and docking of the robotic instruments to successfully reach and remove the tumor. Despite these complexities, the patient had a successful surgery and subsequent recovery.

He was kept under observation in intensive care and was shifted to a general bed the day after the surgery. By the third day, he was able to resume a normal diet and was discharged just a week after the procedure.”

“Based on the final biopsy report, the patient will need to undergo chemotherapy. After completing the treatment, he will only require routine blood tests and imaging for surveillance to detect any early recurrence and receive timely treatment. They can continue with their normal life without the need for long-term medications or restrictions,” said Dr Saleem Naik, Senior Consultant, GI Surgery, Amrita Hospital, Faridabad.

The patient had been suffering from intestinal obstruction due to the tumor for the past two months, which rendered him unable to eat and caused significant weight loss. His symptoms included vomiting, inability to eat, weight loss, anemia, and abdominal distension, leading to his admission to the hospital.

The patient said, “I am incredibly grateful to the team at Amrita Hospital for their exceptional care. The robot-assisted surgery not only relieved my symptoms but also improved my quality of life significantly. I can now eat normally and live without the constant pain and discomfort that I was experiencing.”

Robot-assisted surgery shortens hospital stays and accelerates recovery through smaller incisions, reduced pain, and lower infection risk. Enhanced precision allows effective and targeted interventions, facilitating quicker healing. Safety measures include rigorous training for surgeons, multiple system checks, and continuous monitoring of patient vitals and robot performance. Surgeons retain full control of the instruments, with the ability to override the system if necessary. These protocols ensure the effectiveness and reliability of robotic surgery, leading to improved patient outcomes and more efficient recovery processes.

Powered by WPeMatico